Long-term prognosis after medical treatment of Graves' disease in a northern Swedish population 2000-2010

European Journal of Endocrinology

Volumn 170, Issue 3, 2014, Pages 419-427

  Mohlin, Eric ^a   Nyström, Helena Filipsson ^b,c   Eliasson, Mats ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; LIOTHYRONINE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ADULT; AGEUSIA; AGRANULOCYTOSIS; ARTHRALGIA; ARTICLE; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; FEMALE; FOLLOW UP; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GOITER; GRANULOCYTOPENIA; GRAVES DISEASE; HUMAN; HYPERTRANSAMINASEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RASH; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SMOKING; SURVIVAL; SWEDEN; THYROID SURGERY;

ADULT; ANTITHYROID AGENTS; FEMALE; GOITER; GRAVES DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SMOKING; SWEDEN; THYROXINE; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 84896268555     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0811     Document Type: Article

References (36)

1. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y & Izumi M. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991 1 129-135. (doi:10.1089/thy.1991.1.129)
2. Burch HB, Burman KD & Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. Journal of Clinical Endocrinology and Metabolism 2012 97 4549-4558. (doi:10.1210/jc.2012-2802)
3. Abraham P, Avenell A, McGeoch SC, Clark LF & Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database of Systematic Reviews 2010 CD003420. (doi:10.1002/14651858.CD003420.pub4)
4. Anagnostis P, Adamidou F, Polyzos SA, Katergari S, Karathanasi E, Zouli C, Panagiotou A & Kita M. Predictors of long-term remission in patients with Graves' disease: a single center experience. Endocrine 2013 44 448-453. (doi:10.1007/s12020-013-9895-0)
5. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC & Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2000 85 1038-1042. (doi:10.1210/jcem.85.3.6430)
6. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E & Pinchera A. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997 7 369-375. (doi:10.1089/thy.1997.7.369)
7. Winsa B, Dahlberg A, Jansson R, Agren H & Karlsson FA. Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. Acta Endocrinologica 1990 122 722-728. (doi:10.1530/acta.0.1220722)
8. Chowdhury TA & Dyer PH. Clinical, biochemical and immunological characteristics of relapsers and non-relapsers of thyrotoxicosis treated with anti-thyroid drugs. Journal of Internal Medicine 1998 244 293-297. (doi:10.1046/j.1365-2796.1998.00320.x)
9. Glinoer D, de Nayer P, Bex M & Belgian Collaborative Study Group on Graves' Disease. Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. European Journal of Endocrinology 2001 144 475-483. (doi:10.1530/eje.0.1440475)
10. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA & Aanderud S. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. European Journal of Endocrinology 2002 147 583-589. (doi:10.1530/eje.0.1470583)
11. Quadbeck B, Roggenbuck U, Janssen OE, Hahn S, Mann K, Hoermann R & Basedow Study Group. Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs. Experimental and Clinical Endocrinology & Diabetes 2006 114 406-411. (doi:10.1055/s-2006-924065)
12. Eckstein AK, Lax H, Losch C, Glowacka D, Plicht M, Mann K, Esser J & Morgenthaler NG. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clinical Endocrinology 2007 67 607-612. (doi:10.1111/j.1365-2265.2007.02933.x)
13. Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, De Martino E & Rosei EA. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. Endocrine Journal 2007 54 713-720. (doi:10.1507/endocrj.K06-069)
14. Carella C, Mazziotti G, Sorvillo F, Piscopo M, CioffiM, Pilla P, Nersita R, Iorio S, Amato G, Braverman LE et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 2006 16 295-302. (doi:10.1089/thy.2006.16.295)
15. Quadbeck B, Hoermann R, Roggenbuck U, Hahn S,Mann K, Janssen OE & Basedow Study Group. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. Thyroid 2005 15 1047-1054. (doi:10.1089/thy.2005.15.1047)
16. Choo YK, Yoo WS, Kim DW & Chung HK. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease. Thyroid 2010 20 949-954. (doi:10.1089/thy.2009.0126)
17. Andersson M, Berg G, Eggertsen R, Filipsson H, Gramatkovski E, Hansson M, Hulthen L, Milakovic M & Nystrom E. Adequate iodine nutrition in Sweden: a cross-sectional national study of urinary iodine concentration in school-age children. European Journal of Clinical Nutrition 2009 63 828-834. (doi:10.1038/ejcn.2008.46)
18. Filipsson Nystrom H, Andersson M, Berg G, Eggertsen R, Gramatkowski E, Hansson M, Hulthen L, Milakovic M & Nystrom E. Thyroid volume in Swedish school children: a national, stratified, population-based survey. European Journal of Clinical Nutrition 2010 64 1289-1295. (doi:10.1038/ejcn.2010.162)
19. Holm LE & Alinder I. Relapses after thionamide therapy for Graves' disease. Acta Medica Scandinavica 1982 211 489-492. (doi:10.1111/j.0954-6820. 1982.tb01987.x)
20. Berglund J, Christensen SB, Dymling JF & Hallengren B. The incidence of recurrence and hypothyroidism following treatment with antithyroid drugs, surgery or radioiodine in all patients with thyrotoxicosis in Malmo during the period 1970-1974. Journal of Internal Medicine 1991 229 435-442. (doi:10.1111/j.1365-2796.1991.tb00371.x)
21. Pedersen IB, Knudsen N, Perrild H, Ovesen L & Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clinical Endocrinology 2001 55 381-390. (doi:10.1046/j.1365- 2265.2001.01347.x)
22. Nystrom HF, Berg G, Eggertsen R, Hulthen L & Milakovic M. Swedish iodination of salt has decreased the incidence of goiter. But low use of iodinated salt in the schools raises concerns for the future. Lakartidningen 2012 109 90-93.
23. Bulow Pedersen I, Laurberg P, Knudsen N, Jorgensen T, Perrild H, Ovesen L & Rasmussen LB. Increase in incidence of hyperthyroidism predominantly occurs in young people after iodine fortification of salt in Denmark. Journal of Clinical Endocrinology and Metabolism 2006 91 3830-3834. (doi:10.1210/jc.2006- 0652)
24. Sundick RS, Bagchi N & Brown TR. The role of iodine in thyroid autoimmunity: from chickens to humans: a review. Autoimmunity 1992 13 61-68. (doi:10.3109/08916939209014636)
25. 3 at time of diagnosis in nosological types of thyrotoxicosis: a population-based study. European Journal of Endocrinology 2013 169 537-545. (doi:10.1530/EJE-13-0533)
26. Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D, Poertl S, Weglohner W, Hollidt JM, Quadbeck B et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. Journal of Clinical Endocrinology and Metabolism 1999 84 90-97. (doi:10.1210/jcem.84.1.5415)
27. Stegmayr B, Eliasson M & Rodu B. The decline of smoking in northern Sweden. Scandinavian Journal of Public Health 2005 33 321-324 (discussion 243). (doi:10.1080/14034940510032301)
28. Eliasson M, Asplund K, Evrin PE & Lundblad D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study. Atherosclerosis 1995 113 41-53. (doi:10.1016/0021-9150(94)05425-I)
29. Wiersinga WM. Smoking and thyroid. Clinical Endocrinology 2013 79 145-151. (doi:10.1111/cen.12222)
30. Carle A, Bulow Pedersen I, Knudsen N, Perrild H, Ovesen L, Banke Rasmussen L, Jorgensen T & Laurberg P. Smoking cessation is followed by a sharp but transient rise in the incidence of overt autoimmune hypothyroidism - a population-based, case-control study. Clinical Endocrinology 2012 77 764-772. (doi:10.1111/j.1365-2265.2012.04455.x)
31. Effraimidis G, Tijssen JG &Wiersinga WM. Discontinuation of smoking increases the risk for developing thyroid peroxidase antibodies and/or thyroglobulin antibodies: a prospective study. Journal of Clinical Endocrinology and Metabolism 2009 94 1324-1328. (doi:10.1210/jc.2008-1548)
32. Effraimidis G, Strieder TG, Tijssen JG & Wiersinga WM. Natural history of the transition from euthyroidism to overt autoimmune hypo- or hyperthyroidism: a prospective study. European Journal of Endocrinology 2011 164 107-113. (doi:10.1530/EJE-10-0785)
33. Tajiri J & Noguchi S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid 2004 14 459-462. (doi:10.1089/105072504323150787)
34. Westerlund E & Eliasson M. High risk of thyrotoxicosis in Northern Sweden. Retrospective survey of medical records for 2004-2005 in Norrbothnia. Lakartidningen 2008 105 3196-3201.
35. Abraham-Nordling M, Torring O, Lantz M, Hallengren B, Ohrling H, Lundell G, Calissendorff J, Jorneskog G & Wallin G. Incidence of hyperthyroidism in Stockholm, Sweden, 2003-2005. European Journal of Endocrinology 2008 158 823-827. (doi:10.1530/EJE-07-0877)
36. Abraham-Nordling M, Bystrom K, Torring O, Lantz M, Berg G, Calissendorff J, Nystrom HF, Jansson S, Jorneskog G, Karlsson FA et al. Incidence of hyperthyroidism in Sweden. European Journal of Endocrinology 2011 165 899-905. (doi:10.1530/EJE-11-0548)